Otsuka Presents Final Phase 3 VISIONARY Results for VOYXACT at ASN
Filed with TSE · · 4 pages · English
Otsuka Holdings Co., Ltd. on 6ix
Story so far
- Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT in U.S.
- Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
- Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
Earlier from Otsuka
- Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT in U.S.
- NDA Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA RTOR Program
- Notice regarding the status of share repurchases
- Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
- Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Later from Otsuka
- Consolidated Financial Results for the Nine-Month Period Ended September 30, 2026 [IFRS]
- Notice Regarding Transition to a Company with an Audit and Supervisory Committee
- Notification of Completion of Share Repurchase and Number of Treasury Stock to be Cancelled
Follow Otsuka into a list and get an email when it puts out news.
Follow Otsuka